Literature DB >> 29307367

Measles and Rubella Global Strategic Plan 2012-2020 midterm review.

W A Orenstein1, A Hinman2, B Nkowane3, J M Olive4, A Reingold5.   

Abstract

KEY HIGHLIGHTS: 1. Measles eradication is the ultimate goal but it is premature to set a date for its accomplishment. Existing regional elimination goals should be vigorously pursued to enable setting a global target by 2020. 2. The basic strategic approaches articulated in the Global Measles and Rubella Strategic Plan 2012-2020 are valid to achieve the goals but have not been fully implemented (or not appropriately adapted to local situations). 3. The report recommends a shift from primary reliance on supplementary immunization activities (SIAs) to assure two doses of measles-containing vaccine (MCV) are delivered to the target population to primary reliance on ongoing services to assure administration of two doses of MCV. Regular high quality SIAs will still be necessary while ongoing services are being strengthened. 4. The report recommends a shift from primary reliance on coverage to measure progress to incorporating disease incidence as a major indicator. 5. The report recommends that the measles/rubella vaccination program be considered an indicator for the quality of the overall immunization program and that measles/rubella incidence and measles and rubella vaccination coverage be considered as primary indicators of immunization program performance. 6. Polio transition presents both risks and opportunities: risks should be minimized and opportunities maximized. 7. A school entry immunization check could contribute significantly to strengthening overall immunization services with assurance that recommended doses of measles and rubella vaccines as well as other vaccines have been delivered and providing those vaccines at that time if the child is un- or under-vaccinated. 8. Program decisions should increasingly be based on good quality data and appropriate analysis. 9. The incorporation of rubella vaccination into the immunization program needs to be accelerated - it should be accorded equivalent emphasis as measles. 10. Outbreak investigation and response are critical but the most important thing is to prevent outbreaks.
Copyright © 2017 World Health Organization. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Evaluation; Immunization; Measles; Recommendations; Rubella

Mesh:

Substances:

Year:  2018        PMID: 29307367     DOI: 10.1016/j.vaccine.2017.09.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  Response to third rubella vaccine dose.

Authors:  Lotta Siira; Hanne Nøkleby; Regine Barlinn; Øystein R Riise; Ingeborg S Aaberge; Susanne G Dudman
Journal:  Hum Vaccin Immunother       Date:  2018-06-21       Impact factor: 3.452

2.  A Microneedle Patch for Measles and Rubella Vaccination Is Immunogenic and Protective in Infant Rhesus Macaques.

Authors:  Jessica C Joyce; Timothy D Carroll; Marcus L Collins; Min-Hsin Chen; Linda Fritts; Joseph C Dutra; Tracy L Rourke; James L Goodson; Michael B McChesney; Mark R Prausnitz; Paul A Rota
Journal:  J Infect Dis       Date:  2018-06-05       Impact factor: 5.226

Review 3.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

4.  Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].

Authors:  Ikechukwu Adigweme; Edem Akpalu; Mohammed Yisa; Simon Donkor; Lamin B Jarju; Baba Danso; Anthony Mendy; David Jeffries; Abdoulie Njie; Andrew Bruce; Michael Royals; James L Goodson; Mark R Prausnitz; Devin McAllister; Paul A Rota; Sebastien Henry; Ed Clarke
Journal:  Trials       Date:  2022-09-14       Impact factor: 2.728

5.  [Elimination of measles in the WHO European Region-challenges persist].

Authors:  Mark Muscat; Myriam Ben Mamou; Simarjit Singh; Catharina de Kat; Dragan Jankovic; Shahin Huseynov; Sergei Deshevoi; Siddhartha Datta; Patrick O'Connor
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2019-04       Impact factor: 1.513

6.  Accelerating measles and rubella elimination through research and innovation - Findings from the Measles & Rubella Initiative research prioritization process, 2016.

Authors:  Gavin B Grant; Balcha G Masresha; William J Moss; Mick N Mulders; Paul A Rota; Saad B Omer; Abigail Shefer; Jennifer L Kriss; Matt Hanson; David N Durrheim; Robert Linkins; James L Goodson
Journal:  Vaccine       Date:  2019-03-20       Impact factor: 3.641

7.  Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey.

Authors:  Jennifer L Kriss; Gavin B Grant; William J Moss; David N Durrheim; Abigail Shefer; Paul A Rota; Saad B Omer; Balcha G Masresha; Mick N Mulders; Matt Hanson; Robert W Linkins; James L Goodson
Journal:  Vaccine       Date:  2019-03-18       Impact factor: 3.641

8.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2020-04-20

9.  The introduction of 'No jab, No school' policy and the refinement of measles immunisation strategies in high-income countries.

Authors:  Filippo Trentini; Piero Poletti; Alessia Melegaro; Stefano Merler
Journal:  BMC Med       Date:  2019-05-17       Impact factor: 8.775

10.  Descriptive epidemiology of measles cases in Bauchi State, 2013-2018.

Authors:  Polycarp Uchechukwu Ori; Ayo Adebowale; Chukwuma David Umeokonkwo; Ugochukwu Osigwe; Muhammad Shakir Balogun
Journal:  BMC Public Health       Date:  2021-07-05       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.